Summit Therapeutics (SMMT) news
Recent news
Summit Therapeutics - Study meets key secondary endpoints of PFS and ORR
Summit Therapeutics Inc. (Nasdaq: SMMT) announced updated results from its global Phase III HARMONi clinical trial evaluating ivonescimab, a bispecific antibody, in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who had previously received…
AInvest Wire · 5d agoAkeso - Study meets key secondary endpoints of progression-free survival and objective response rate
Akeso Inc. (HKEX: 9926.HK) recently reported that its Phase II clinical trial of ivonescimab in first-line metastatic colorectal cancer (mCRC) met key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR). The study, conducted in collaboration with Summit…
AInvest Wire · 5d agoSummit Therapeutics notes Akeso received NMPA ivonesimab NDA
Summit Therapeutics has announced that Akeso, its subsidiary in China, has received approval from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) of ivonescimab in combination with chemotherapy for the first-line treatment of patients with squamous non-small…
AInvest Wire · Aug 12, 2026Summit Therapeutics - to offer and sell common stock up to $380 mln aggregate through sales agent - SEC filing
Summit Therapeutics Inc. has filed with the U.S. Securities and Exchange Commission (SEC) to offer and sell up to $380 million in aggregate principal amount of its common stock through a sales agent, according to a recent SEC filing [1]. The offering is part of the company’s ongoing efforts to…
AInvest Wire · Jul 23, 2026Summit Therapeutics shares extend gain to 7.4% in premarket
Summit Therapeutics shares rose 2.5% during regular trading and extended gains to 7.4% in premarket trading on July 22, 2026, with the latest progress reflecting premarket movement, per market reports.
AInvest Wire · Jul 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.